Abstract 1824P
Background
Patients with advanced prostate cancer are commonly treated with novel hormonal therapy (NHT). However, treatment patterns following NHT remained unclear. This study evaluated treatment patterns among metastatic castration-resistant prostate cancer (mCRPC) patients with prior NHT.
Methods
This study used the Flatiron Health electronic health records data between 1/1/2013-7/31/2022. NHT-experienced mCRPC patients with ≥ 1 line of therapy (LOT) in the mCRPC setting and without chemotherapy in the last 365 days were included. The first LOT in the post-NHT mCRPC setting was defined as index line. Treatment patterns in the post-NHT mCRPC setting were summarized.
Results
A total of 804 patients (median follow-up: 10.6 months) were included. Of these, 239 (30%) patients used enzalutamide as index LOT, 191 (24%) patients used abiraterone, 171 (21%) used docetaxel, and 203 (25%) used other treatment (Table). Patients receiving prior NHT in the non-metastatic castration-resistant or metastatic castration-sensitive settings were more likely to cycle to NHTs than those receiving prior NHT in the mCRPC setting. The median time on treatment for index LOT was 4.1 months. A total of 126 (16%) patients died within 90 days after index LOT while 494 (61%) patients received a 2nd post-NHT LOT. Subsequently, 104 (13%) patients died within 90 days after the 2nd post-NHT LOT while 265 (33%) patients received a 3rd post-NHT LOT. Most patients received chemotherapy while fewer patients received NHTs in the 2nd and 3rd post-NHT LOTs. Commonly observed treatment sequences included index enzalutamide followed by docetaxel (N=62, 8%), index docetaxel followed by other chemotherapy (N=54, 7%), and index abiraterone followed by docetaxel (N=48, 6%).
Table: 1824P
Treatment patterns in the post-NHT mCRPC setting
NHT-experienced patients with mCRPC (N = 804) | |
Index line (the 1 st post-NHT LOT) | 804 (100%) |
Enzalutamide | 239 (30%) |
Abiraterone | 191 (24%) |
Docetaxel | 171 (21%) |
Other NHTs | 29 (4%) |
Radium-223 | 22 (3%) |
Other chemotherapy | 21 (3%) |
Poly adenosine diphosphate ribose polymerase inhibitors (PARPi) | 8 (1%) |
Other | 123 (15%) |
The 2 nd post-NHT LOT | 494 (61%) |
Docetaxel | 145 (18%) |
Other chemotherapy | 90 (11%) |
Enzalutamide | 58 (7%) |
Abiraterone | 39 (5%) |
Radium-223 | 29 (4%) |
Other NHTs | 21 (3%) |
PARPi | 15 (2%) |
Other | 97 (12%) |
The 3 rd post-NHT LOT | 265 (33%) |
Other chemotherapy | 96 (12%) |
Docetaxel | 58 (7%) |
Enzalutamide | 17 (2%) |
Radium-223 | 16 (2%) |
PARPi | 10 (1%) |
Other NHTs | 9 (1%) |
Abiraterone | 7 (1%) |
Other | 52 (6%) |
Conclusions
The real-world treatment patterns in the post-NHT mCRPC setting are heterogeneous, but the majority of patients attempted additional NHT followed by chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was undertaken by Analysis Group Inc. sponsored by Bristol Myers Squibb.
Disclosure
V.K. Narayan: Financial Interests, Institutional, Research Grant: Pfizer, Janssen Oncology, Merck, Regeneron, BMS, TMunity Therapeutics; Financial Interests, Personal, Advisory Board: BMS, Pfizer, Janssen Oncology, Exelixis, Myovant Sciences, Regeneron, Amgen, AstraZeneca. M. Patel, S. Teitsson, L.C. Rosenblatt: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS. X. Yin: Financial Interests, Personal, Full or part-time Employment: BMS. K.A. Betts: Financial Interests, Institutional, Funding, Keith A. Betts is an employee of Analysis Group. Other description if needed Analysis Group received consulting fees from BMS to conduct this study: BMS. I. Pivneva: Financial Interests, Institutional, Funding, I. Pivneva is a full-time employee of Analysis Group. Analysis Group received consulting fees from BMS to conduct this study: BMS. S. Gao: Financial Interests, Institutional, Funding, Sophie Gao is a full-time employee of Analysis Group. Analysis Group received consulting fees from BMS to conduct this study: BMS. M. Sundar: Financial Interests, Institutional, Funding, Manasvi Sundar is an employee of Analysis Group. Other description if needed Analysis Group received consulting fees from BMS to conduct this study: BMS.
Resources from the same session
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1922P - Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Presenter: Nadia Hindi Muñiz
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15